MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

Voice Analytics and AI to Transform Drug and Alcohol Testing

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.

• MindBio Therapeutics is developing AI-driven voice analysis technology to detect drug and alcohol impairment without relying on invasive and time-consuming breath, saliva, or laboratory testing.
• The company’s platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples.
• The new technology is seen applicable to both workplace and non-workplace settings, with the global alcohol and drug testing devices market projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033, reflecting rising safety requirements and stricter regulatory oversight.
• Mining is MindBio’s initial commercial focus, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening, with other areas of application including aviation, construction, call centers, law enforcement, and mental health settings where high-volume screening is expensive and time consuming.

The market for workplace drug and alcohol detection is expanding as employers face increasing pressure to improve safety while reducing the cost and friction of traditional testing methods. This creates a unique opportunity for companies attempting to modernize a process that remains heavily dependent on breathalyzers, urine testing, and laboratory analysis.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, is positioning itself in that space with an alternative approach: using artificial intelligence and voice analytics to estimate drug and alcohol intoxication levels from short speech samples. The company has spent several years conducting drug and alcohol research while developing machine learning models designed to detect impairment through speech. Rather than relying on physical samples such as breath, saliva, or blood, the system analyzes voice patterns captured through a standard microphone.

Management says the platform evaluates more than 140 acoustic parameters and has been trained using a dataset exceeding 50 million data points. The goal is to identify measurable speech changes associated with intoxication and deliver a rapid assessment in real time.

Traditional workplace testing is often expensive, disruptive, and difficult to scale. In industries with thousands of workers entering safety-sensitive environments every day, routine alcohol and drug testing can create operational bottlenecks and significant administrative costs. This is particularly relevant in mining, aviation, construction, and transportation, where regulators often require formal testing protocols and where a single impairment-related incident can carry serious human and financial consequences.

According to market research published by Data Insights Market, the global alcohol and drug testing devices market is expected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, representing a 7% compound annual growth rate. (https://ibn.fm/0dkYp). That growth is being driven by stricter workplace compliance rules, increasing concerns around substance misuse, and wider adoption of point-of-care testing that allows immediate results rather than delayed laboratory reporting.

Portable and handheld systems are gaining share because employers increasingly want testing solutions that can be used in remote locations or high-volume environments. This trend aligns with MindBio’s development of Edge AI kiosks intended for industrial deployment.

The proposed use case is simple. A worker arriving at a mine site, construction project, or industrial facility would provide a short voice sample at an entry point kiosk. The system would then analyze the recording and flag indicators of alcohol or drug impairment almost immediately. This could reduce dependence on invasive testing procedures and allow management to screen larger workforces more efficiently. It may also help address one of the persistent limitations of conventional testing: the balance between compliance and productivity.

MindBio’s initial commercial focus has been on the mining industry, particularly operations in South America. These sites often involve remote locations, rotating workforces, and high-risk physical tasks where fatigue, impairment, and human error can create outsized operational risks.

The company has indicated that field testing of its kiosk systems is expected during the second quarter of 2026. If successful, that could provide an important commercial validation point for investors assessing whether the technology can move beyond development and into enterprise adoption.

The opportunity, however, extends beyond mining. Management has identified call centers, law enforcement, and mental health settings as additional target markets, alongside regulated sectors such as aviation and construction. In these environments, high-volume screening can be difficult to administer using traditional methods.

Call centers, for example, face challenges related not only to alcohol and drug use but also to fatigue, stress, and mental wellness. Voice analytics may provide employers with another operational tool where speech is already central to the work environment. Law enforcement agencies and mental health services may also benefit from rapid, non-invasive assessment tools where behavioral indicators matter but immediate laboratory testing is impractical.

For more information, visit the company’s website at www.MindBioTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN